title: [Time course of changes in iron metabolic and oxidative-antioxidative system parameters in patients with acute myeloid leukemia].
abstract: OBJECTIVE
  To study an association between iron metabolism, free radical oxidation (FRO), and antioxidative system (AOS) in patients with acute myeloid leukemia (AML) during intensive chemotherapy.
  
  
  METHODS
  AML patients (n = 14) with a median age of 46 years received 7+3 courses (n = 3) containing cytarabine > or = 1 g/m2/introduction (n = 8) and myeloablative conditioning regimen before hematopoietic stem cell transplantation (n = 3). The concentrations of iron, ferritin, transferrin saturation (TFS), and malonic dialdehyde and the activity of superoxide dismutase (SOD), ceruloplasmin (CP), and catalase were investigated in their sera. The investigations were performed before and after chemotherapy and during hemopoietic recovery and rehospitalization. RESULTS; After therapy termination, there was a significant increase in TFS (6.8% vs 41.9%; p < 0.0001), which gave way to its reduction during hemopoietic recovery (89.5% vs 96.8%; p = 0.003). The activity of antioxidant enzymes was found to be altered at a time. That of catalase was enhanced throughout cytopenia (3.8 and 3.3 vs 5.7 conventional units (CU)/ml; p = 0.028 and p = 0.011). The lower activity of SOD (21.0 vs 41.0 CU/ml; p = 0.018) and the higher activity of CP (1.1 vs 0.8 g/l) were ascertained when leukocyte count increased up to > or = 1 x 10(9)/l.
  
  
  CONCLUSIONS
  After intensive cytostatic therapy, there was a phasic TFS increase accompanied by the compensatory change in AOS activity, which is aimed at neutralizing FRO products.
authors.forename: S V
authors.initials: SV
authors.lastname: Gritsaev
authors.forename: D I
authors.initials: DI
authors.lastname: Shikhbabaeva
authors.forename: L P
authors.initials: LP
authors.lastname: Rybakova
authors.forename: A N
authors.initials: AN
authors.lastname: Sergeev
authors.forename: S I
authors.initials: SI
authors.lastname: Kapustin
authors.forename: K M
authors.initials: KM
authors.lastname: Abdulkadyrov
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism*; D002374:Catalase / Q000097:blood; D002570:Ceruloplasmin / Q000378:metabolism; D005260:Female; D005609:Free Radicals / Q000378:metabolism*; D006801:Humans; D007501:Iron / Q000097:blood / Q000378:metabolism*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D013482:Superoxide Dismutase / Q000097:blood; D014168:Transferrin / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D005609:Free Radicals; D014168:Transferrin; D008315:Malondialdehyde; D007501:Iron; D002374:Catalase; D013482:Superoxide Dismutase; D002570:Ceruloplasmin